Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
Journal of Clinical Oncology, 07/03/08
Kumar B et al. - In a study to prospectively identify markers of response to therapy and outcome in an organ-sparing trial for advanced oropharyngeal cancer, it was shown that low epidermal growth factor receptor (EGFR) and high p16 (or higher human papillomavirus [HPV] titer) expression are markers of good response to organ-sparing therapy and outcome, whereas high EGFR expression, combined low p53/high Bcl-xL expression, female sex, and smoking are associated with a poor outcome
Methods- Pretreatment biopsies were examined for expression of EGFR, p16, Bcl-xL, and p53 as well as for p53 mutation
- These markers were assessed for association with high-risk HPV, response to therapy, and survival
- Pt variables included smoking history, sex, age, primary site, tumor stage, and nodal status
- EGFR expression was inversely associated with response to induction chemotherapy (IC), chemotherapy/radiotherapy (CRT), overall survival (OS), and disease-specific survival (DSS) and was directly associated with current smoking, female sex, and lower HPV titer
- HPV titer was significantly associated with p16 expression; p16 was significantly associated with response to IC, CRT, OS, and DSS
- As combined markers, lower HPV titer and high EGFR expression were associated with worse OS and DSS
- In 36 of 42 biopsies, p53 was wild-type, and only 1 HPV-positive tumor had mutant p53
- Combination of low p53 and high Bcl-xL expression was associated with poor OS and DSS
| Previous Article | Next Article |
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of ER-α36, a novel variant of estrogen receptor-α, and resistance to tamoxifen treatment in breast cancer
Journal of Clinical Oncology, 06/04/09
Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia
Medical Oncology, 06/05/09
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor-alpha; therapy: Is there a need for more comprehensive screening procedures?
Arthritis Care and Research , 06/03/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Cancer Incidence among Patients with Alcohol Use Disorders—Long-Term Follow-Up
Alcohol and Alcoholism , 06/11/09
Cervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties
Surgical Oncology, 05/27/09
Radiation therapy for minor salivary gland carcinoma
The Laryngoscope, 06/11/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience
Medical Oncology, 06/05/09
American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Journal of Clinical Oncology, 07/01/09
nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
Breast Cancer Research and Treatment, 06/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


